Core Viewpoint - The article emphasizes the importance of maintaining a price trend for successful short-term investing, highlighting that a price increase of 4.5% over the past four weeks indicates a sustained trend for Mirion Technologies, Inc. [2] Group 1: Stock Performance and Trends - Mirion Technologies, Inc. (MIR) has experienced a significant price increase of 59.6% over the past 12 weeks, reflecting strong investor interest and potential upside [6] - The stock is currently trading at 87.7% of its 52-week high-low range, suggesting it may be on the verge of a breakout [12] - The Zacks Rank for MIR is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [7] Group 2: Analyst Recommendations - The Average Broker Recommendation for MIR is 1 (Strong Buy), indicating high optimism from the brokerage community regarding the stock's near-term performance [4] - The Zacks Rank stock-rating system has a strong track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988, suggesting that stocks with strong ratings are likely to perform well [3] Group 3: Investment Strategies - The "Recent Price Strength" screen is highlighted as a useful tool for investors looking to identify stocks on an upward trend supported by strong fundamentals [5] - The article suggests that confirming sound fundamentals and positive earnings estimate revisions is crucial for maintaining stock momentum and achieving profitable trades [10]

Group 1 - Mirion Technologies, Inc. is part of the Business Services sector, which includes 305 individual stocks and currently holds a Zacks Sector Rank of 4 [1] - Year-to-date, Mirion Technologies has returned approximately 74.7%, outperforming the average gain of 23.4% for Business Services stocks [2] - Within the Technology Services industry, which consists of 162 companies, Mirion Technologies ranks 56 in the Zacks Industry Rank and has outperformed the industry average return of 58.2% this year [3] Group 2 - The Zacks Consensus Estimate for Mirion Technologies' full-year earnings has increased by 6.5% over the past quarter, indicating improved analyst sentiment [5] - Mirion Technologies currently holds a Zacks Rank of 2 (Buy), suggesting a positive earnings outlook [7] - Investors should monitor Mirion Technologies and Grab Holdings Limited as both companies are expected to maintain strong performance in the Business Services sector [9]

Core Insights - The article emphasizes the importance of identifying and sustaining trends in short-term investing, highlighting that a solid trend can lead to successful trading [1][2]. Stock Performance - Mirion Technologies, Inc. (MIR) has shown a significant price increase of 81.1% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 18.2% in the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, MIR is trading at 90.7% of its 52-week high-low range, indicating a potential breakout [5]. Fundamental Strength - MIR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like MIR that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [8].

Revenue Growth - The company reported a significant increase in revenue, with a year-over-year growth of 15% for the third quarter of 2024, reaching $500 million[17]. - The company anticipates a revenue growth of 10% to 12% for the next quarter, projecting revenues between $550 million and $560 million[17]. - Total revenues for the three months ended September 30, 2024, were $206.8 million, an increase of 8.8% compared to $191.2 million for the same period in 2023[21]. - Total revenues for the nine months ended September 30, 2024, were $606.5 million, a 6.3% increase from $570.5 million for the same period in 2023[156]. - The company reported a revenue of $149.5 million for point-in-time recognition for the three months ended September 30, 2024, compared to $128.0 million in the same period of 2023, marking a 16.7% increase[157]. User Growth - User data showed a 20% increase in active users, totaling 2 million users as of September 30, 2024[17]. Market Expansion - The company is expanding its market presence in Asia, targeting a 25% increase in market share by the end of 2025[17]. - The company is actively exploring strategic partnerships to enhance its competitive positioning in the market[17]. Research and Development - Ongoing research and development efforts have led to advancements in technology, with a budget increase of 30% for R&D in 2024[17]. - Research and development expenses increased to $10.2 million for the three months ended September 30, 2024, compared to $7.9 million in the same period last year, indicating a focus on innovation[21]. Financial Performance - Gross profit for the three months ended September 30, 2024, was $92.9 million, up from $80.8 million in the same period last year, reflecting a gross margin improvement[21]. - The company reported a gross profit margin of 44.9% for the three months ended September 30, 2024, compared to 42.3% for the same period in 2023[21]. - The net loss attributable to Mirion Technologies, Inc. for the three months ended September 30, 2024, was $13.6 million, compared to a net loss of $12.1 million for the same period in 2023[21]. - Operating expenses for the three months ended September 30, 2024, totaled $94.5 million, slightly higher than $91.9 million in the prior year[21]. - The company experienced a foreign currency translation gain of $29.5 million for the three months ended September 30, 2024, compared to a loss of $20.3 million in the same period last year[23]. Acquisitions and Integration - The company has successfully integrated two recent acquisitions, which are projected to enhance operational efficiency by 15%[17]. - The acquisition of ec Software Solutions, LLC and NUMA LLC was completed for a purchase price of $31.4 million, including $14.5 million in intangible assets and $17.4 million in goodwill[70]. - The Company recorded a $1.4 million net increase in goodwill related to the ec acquisition during the nine months ended September 30, 2024[70]. Debt and Financing - As of September 30, 2024, total third-party debt amounted to $696.8 million, slightly increasing to $698.4 million by December 31, 2023[8]. - The 2021 Credit Agreement includes an $830.0 million senior secured first lien term loan facility and a $90.0 million senior secured revolving facility, with the term loan maturing on October 20, 2028[100]. - The interest rate on the term loan was 6.85% as of September 30, 2024, down from 8.40% on December 31, 2023, following an amendment that reduced the applicable margin rate[106]. Operational Efficiency - Supply chain improvements have reduced costs by 10%, positively impacting the overall profit margins[17]. - Total accrued expenses and other current liabilities amounted to $103.4 million as of September 30, 2024, compared to $95.6 million on December 31, 2023, reflecting an increase of 8.5%[83]. Risks and Challenges - Future risks include potential impacts from geopolitical tensions, particularly between the United States and China, which could affect operations[17]. - The company is actively monitoring inflation and interest rates, which have increased debt service costs[206]. Stockholder Equity - As of September 30, 2023, total stockholders' equity was $1,543.3 million, with an accumulated deficit of $490.2 million[28]. - The balance of total stockholders' equity as of December 31, 2023, was $1,550.0 million, with an accumulated deficit of $505.4 million[30]. Segment Performance - Medical segment revenues reached $74.1 million in Q3 2024, up from $68.8 million in Q3 2023, while Technologies segment revenues increased to $132.7 million from $122.4 million[153]. - Total segment income from operations for Q3 2024 was $18.7 million, compared to $9.4 million in Q3 2023, indicating a significant improvement in operational performance[153]. Restructuring and Costs - Total restructuring expenses for the nine months ended September 30, 2024, amounted to $4.7 million, compared to $1.6 million for the same period in 2023[189]. - The Company incurred severance and employee costs of $1.5 million for the three months ended September 30, 2024, and $0.3 million for the same period in 2023[184].

| --- | --- | |------------------------------------------------------------|-------| | | | | | | | | | | Third Quarter 2024 Earnings Presentation October 29, 2024 | | | | | | | | | | | Q3 2024 EARNINGS PRESENTATION Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate", "believe", "continue", "could", "estimate", "expect", "hope", "intend", "may", "might", "pl ...

Financial Data and Key Metrics Changes - The company reported third quarter revenue of $207 million, an 8% increase compared to the same period last year [6][28] - Adjusted EPS was $0.08 per share, and adjusted EBITDA was $45.7 million, reflecting a 180 basis point margin improvement year-over-year [6][28] - Organic revenue growth was 6.1%, with adjusted EBITDA margins at 22.1%, marking the fifth consecutive quarter of margin expansion [29][30] Business Line Data and Key Metrics Changes - The Technologies group revenue grew 8.4% to $132.7 million, with margins up 370 basis points due to strong operating performance [37] - The Medical group revenue increased 7.7% to $74.1 million, with organic growth of 3.2% [35] - The nuclear medicine business saw significant growth, with year-to-date unit growth in dose calibrator shipments at 18% compared to 2023 [21] Market Data and Key Metrics Changes - The nuclear power segment experienced a 12% core order growth, excluding large orders from the previous year [16][30] - The backlog at the end of the quarter was $815 million, a 2% increase year-over-year [32] - The company noted a strong pipeline of $300 million to $400 million in new order opportunities expected to be awarded by the end of 2025 [18][55] Company Strategy and Development Direction - The company is focusing on strategic relationships with significant players in the small modular reactor (SMR) market, anticipating a robust demand for clean energy [12][50] - A strategic alliance with Siemens Healthineers aims to expand the global reach of the SunCHECK software platform [23] - The company is committed to improving operational performance through enhanced procurement strategies and business systems [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the evolving macro environment, particularly in nuclear power and cancer care, which are expected to provide favorable tailwinds [7][19] - The company anticipates continued growth in the nuclear medicine market driven by advancements in radiopharmaceutical therapy [20][52] - Management highlighted the improved economic health of the nuclear industry, which is expected to positively impact capital expenditures and operational spending [64][66] Other Important Information - The company has fine-tuned its guidance for revenue growth to 6% to 7% and organic revenue growth to 5% to 6% for the year [39][41] - Adjusted free cash flow guidance was narrowed to $65 million to $75 million [41] - The company plans to provide more detailed insights into its strategy and market positioning at the upcoming Investor Day on December 3rd [42][82] Q&A Session Summary Question: Can you discuss the de-booking that occurred this quarter? - Management explained that the de-booking was related to a contractual dispute on a project in Turkey, but they remain optimistic about regaining some of that business [43][44] Question: What is the status of the Sizewell project? - Management confirmed that the Sizewell contract was part of the expected deal flow and highlighted the significance of their relationship with EDF in securing this contract [47][74] Question: How does the company view the impact of Hyperscalers on future orders? - Management indicated that they are focused on broadening strategic alliances and expect to see additional funding and commitments in the SMR space, which could positively impact orders [49][50] Question: What is the long-term growth outlook for the radiopharmaceutical business? - Management expressed confidence in the growth potential of the radiopharmaceutical market, driven by a robust pipeline of Theranostic drugs and their unique position in the data management space [51][53] Question: Can you provide more details on the backlog by segments? - Management stated that the backlog is composed of 75% Technologies and 25% Medical, with a significant portion of Medical revenue being more short-term oriented [72] Question: How does the company leverage its relationship with EDF for new contracts? - Management elaborated on the strategic relationship with EDF, emphasizing its importance in securing contracts like Sizewell C and the efficiency it brings to the process of building new reactors [73][76]

Exhibit 99.1 News Release Mirion Announces Third Quarter 2024 Financial Results and Updates Full Year Guidance • Revenues for the third quarter increased 8.2% to $206.8 million, compared to $191.2 million in the same period in 2023. • Net loss was $14.0 million in the third quarter, compared to a net loss of $12.9 million in the same period last year. Adjusted EBITDA was $45.7 million, a 17.8% increase from $38.8 million in the same period last year. • Loss from operations margin was 0.8% in the third quart ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39352 Mirion Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 83-0974996 (State or ...

Financial Data and Key Metrics Changes - Revenue grew by 5% in Q2 2024, reaching $207.1 million, with organic growth at 3.6% [14] - Adjusted EBITDA increased by 10.2% to $48.8 million, with adjusted EBITDA margins expanding 110 basis points to 23.6% [14] - Adjusted free cash flow was nearly $9 million in the quarter, contributing to a cash flow positive first half of the year [6] Business Line Data and Key Metrics Changes - Medical segment revenue grew by 7.7% with organic growth of 2.6%, driven by Nuclear Medicine [15] - Technology segment revenue increased by 3.7% with organic growth of 4.1%, supported by strong performance in Nuclear Power [17] - Adjusted EBITDA margin for the Medical segment was 34.3%, a 150 basis point expansion from the previous year [15] Market Data and Key Metrics Changes - Order growth was relatively flat compared to the same period last year, with Nuclear Power orders up by more than 15% [5] - Medical segment order growth was approximately 3%, with strong performance in Dosimetry and Nuclear Medicine [7] - Anticipated changes by CMS for the reimbursement of radio diagnostic drugs in the US market are expected to positively impact market dynamics [31] Company Strategy and Development Direction - A strategic partnership agreement was signed with EDF, making Mirion an exclusive content supplier for their nuclear new build projects over the next two decades [3][4] - The company is focusing on margin performance, with a target of 30% long-term EBITDA margin through procurement initiatives and operational improvements [11][36] - Organizational changes include the appointment of a Chief Revenue Officer and the exit from the Medical Lasers and Alignment business to streamline operations [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the overall health of end markets, particularly in Nuclear Power and Nuclear Medicine, despite facing tough order growth comparisons in the second half of the year [5][25] - The company anticipates that the international markets will improve in 2025, driven by strengthening economic conditions [21][29] - Management remains optimistic about the order pipeline and backlog, expecting to maintain or grow backlog levels in the upcoming quarters [24][25] Other Important Information - The company updated its 2024 financial guidance, raising the adjusted EBITDA target to $195 million to $205 million [6][19] - The company completed the redemption of all outstanding public and private warrants, simplifying its capital structure [22] - An Investor Day is planned for early December to share updated strategy and long-term financial targets with the investment community [22] Q&A Session Summary Question: Health of the order pipeline and backlog expectations - Management indicated that while order rates may not be positive year-over-year in the second half, they expect backlog to be up compared to the same period last year [24][25] Question: Impact of the EDF partnership on existing relationships - The partnership streamlines commercial terms and strengthens competitive positioning, providing greater confidence in future investments [27] Question: Anticipated impact of anticorruption dynamics in China - Management expects 2024 to be the low point for the RTQA business, with improvements anticipated in late 2024 and into 2025 [28][29] Question: Potential impact of CMS changes on reimbursement - Management noted that changes in CMS reimbursement protocols could reduce friction for the prescription of radio diagnostic procedures, potentially increasing demand for their products [31][43] Question: Capital structure improvements - Management stated that significant progress has been made on the balance sheet, with a focus on executing growth plans and improving margins [32][33] Question: Visibility on cash flow generation - Management expressed confidence in generating cash in the second half of the year, aligning with historical performance [40]

Financial Performance - Revenues for Q2 2024 increased by 5.0% to $207.1 million, compared to $197.2 million in Q2 2023[1] - Net loss for Q2 2024 was $12.0 million, an improvement from a net loss of $28.4 million in the same period last year[1] - Adjusted EBITDA for Q2 2024 was $48.8 million, a 10.2% increase from $44.3 million in Q2 2023[1] - Adjusted EBITDA margin improved to 23.6% in Q2 2024, compared to 22.5% in Q2 2023[1] - Gross profit for the three months ended June 30, 2024, was $97.4 million, representing a gross margin of 46.9%, compared to $88.0 million and a gross margin of 44.7% in the prior year[15] - Net loss attributable to Mirion Technologies, Inc. for the three months ended June 30, 2024, was $11.7 million, compared to a net loss of $27.7 million for the same period in 2023[15] - Net loss for the six months ended June 30, 2024, was $38.5 million, a significant improvement from a net loss of $71.3 million for the same period in 2023[17] - Adjusted net income for the three months ended June 30, 2024, was $19.4 million, compared to $15.5 million for the same period in 2023[26] - The company reported a GAAP net loss of $12.0 million for the three months ended June 30, 2024, an improvement from a loss of $28.4 million in the same period of 2023[26] Guidance and Projections - Full year adjusted EBITDA guidance raised to $195 million to $205 million, with revenue growth guidance reiterated at 5% to 7%[2] - Organic revenue growth is expected to be 4% to 6%, with an inorganic growth of approximately 1.5% due to an acquisition[3] - The expected closure of the lasers business is projected to negatively impact organic revenue growth by approximately 30 basis points[3] - Adjusted EPS guidance remains unchanged at $0.37 to $0.42[3] Assets and Liabilities - Total current assets decreased to $515.4 million as of June 30, 2024, from $538.6 million as of December 31, 2023[13] - Total liabilities decreased to $1,063.2 million as of June 30, 2024, down from $1,168.5 million as of December 31, 2023[13] - Cash and cash equivalents as of June 30, 2024, were $122.2 million, a decrease from $128.8 million as of December 31, 2023[13] - Total stockholders' equity increased to $1,564.1 million as of June 30, 2024, from $1,550.0 million as of December 31, 2023[13] Operating Expenses - Operating expenses for the three months ended June 30, 2024, were $95.1 million, a decrease from $98.6 million in the same period of 2023[15] - Research and development expenses for the three months ended June 30, 2024, were $8.8 million, compared to $8.4 million in the prior year[15] - Stock-based compensation expense decreased to $4.0 million for the three months ended June 30, 2024, from $6.0 million in the same period of 2023[26] Strategic Initiatives - The company signed a strategic partnership agreement with EDF to strengthen its position in the nuclear new build market[2] Share Information - The company reported a weighted average of 202.197 million common shares outstanding for the three months ended June 30, 2024[15] - The company had 206,609,792 shares of Class A common stock outstanding as of June 30, 2024[18] - The weighted average common shares outstanding for adjusted earnings per share calculation was 203.005 million for the three months ended June 30, 2024[26] Cash Flow - Net cash provided by operating activities increased to $21.2 million for the six months ended June 30, 2024, compared to $4.4 million for the same period in 2023[17] - Cash, cash equivalents, and restricted cash at the end of the period were $123.8 million, up from $89.1 million at the end of June 30, 2023[17] Foreign Currency Impact - The company experienced a foreign currency loss of $0.3 million for the three months ended June 30, 2024, compared to a gain of $0.2 million in the same period of 2023[26]